4/A: Procept BioRobotics CFO Kevin Waters Amends SEC Filing to Correct Errors in Stock and Option Grants

Kevin Waters, CFO of Procept BioRobotics, files an amended SEC Form 4 to correct clerical errors in the number of shares and options granted on March 6, 2024.

Summary

• Kevin Waters, the EVP and CFO of Procept BioRobotics Corp, filed an amended Form 4 with the SEC.
• The amendment corrects clerical errors in the original filing regarding the number of restricted stock units (RSUs) and stock options granted on March 6, 2024.
• The corrected filing shows Waters acquiring 13,275 shares of common stock in the form of RSUs and 11,563 stock options.
• The RSUs vest 1/4th annually starting March 5, 2024, over three years, contingent upon continued employment.
• The stock options vest 1/48th monthly from March 5, 2024, over four years, also contingent upon continued employment.
• Following the reported transactions, Waters beneficially owns 46,798 shares of common stock and 11,563 stock options.

Sentiment

Score: 7

Explanation: The document is a routine correction of a regulatory filing. The sentiment is neutral as it simply rectifies previously reported information. The vesting schedules are standard and incentivize long-term performance.

Positives

• The correction of the filing ensures transparency and accurate reporting of executive compensation.
• The vesting schedules for RSUs and stock options incentivize continued employment and service by the CFO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation structure for key executives.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a standard practice in the biotechnology industry to align executive interests with shareholder value.
• Vesting schedules of three to four years are common for such grants, incentivizing long-term commitment.
• Comparable companies like Intuitive Surgical or Stryker also utilize similar equity compensation strategies for their executives.

Stakeholder Impact

• Shareholders benefit from accurate reporting of executive compensation.
• Employees, particularly the CFO, are incentivized through equity-based compensation.

Key Dates